A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Bhosale UA; Quraishi N; Yegnanarayan R; Devasthale D
  • Source:
    Journal of basic and clinical physiology and pharmacology [J Basic Clin Physiol Pharmacol] 2015 Jan; Vol. 26 (1), pp. 73-9.
  • Publication Type:
    Comparative Study; Controlled Clinical Trial; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Walter de Gruyter Country of Publication: Germany NLM ID: 9101750 Publication Model: Print Cited Medium: Internet ISSN: 2191-0286 (Electronic) Linking ISSN: 07926855 NLM ISO Abbreviation: J Basic Clin Physiol Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Jun. 2011- : Berlin : Walter de Gruyter
      Original Publication: London, England : Freund Pub. House, c1990-
    • Subject Terms:
      Anti-Inflammatory Agents, Non-Steroidal/*adverse effects ; Arthritis/*drug therapy ; Cyclooxygenase 2 Inhibitors/*adverse effects ; Cyclooxygenase Inhibitors/*adverse effects; Adult ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/etiology ; Cyclooxygenase 2 Inhibitors/therapeutic use ; Cyclooxygenase Inhibitors/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prospective Studies ; Risk Factors
    • Abstract:
      Background: During the past 2 years, a great deal of evaluation has been accomplished on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs), nonselective and selective cyclooxygenase-2 inhibitors (COX-2-Is). Clinical trial databases for nonselective and selective COX-2-Is have shown variable effects on CV risk. There is much controversy regarding the CV safety of these selective and nonselective COX inhibitors (COX-Is). This study was therefore conducted to assess and compare the CV risk of COX-Is in arthritic patients over a period of time.
      Methods: In this prospective comparative study, adult arthritics of either sex who were freshly diagnosed or taking COX-Is for <3 months were included. Patients were grouped into nonselective and selective COX-2-I groups with reference to the treatment they received, whereas arthritics with no history of COX-I treatment were included as controls. CV risk factors like blood pressure (BP), blood sugar level (BSL), lipid profile, and body mass index (BMI) were assessed and compared; the demography of CV risk factors was also studied. Data obtained were analyzed with Student's t-test using OpenEpi statistical software (Andrew G. Dean and Kevin M. Sullivan, Atlanta, GA, USA).
      Results: The study clearly revealed that all NSAIDs exhibit potential CV risk; however, selective COX-2-Is were found to exhibit more CV risk. BMI, BP and lipid profile, the potential CV risk factors, showed significant impairment in a selective COX-2-I group: p<0.01, p<0.001 and p<0.05, respectively, vs. baseline and p<0.05 for BMI and triglycerides vs. nonselective COX-Is.
      Conclusions: This study depicts the impending CV risk of selective COX-2-Is and confirms and reevaluates the results of earlier studies in this regard.
    • Accession Number:
      0 (Anti-Inflammatory Agents, Non-Steroidal)
      0 (Cyclooxygenase 2 Inhibitors)
      0 (Cyclooxygenase Inhibitors)
    • Publication Date:
      Date Created: 20140313 Date Completed: 20150724 Latest Revision: 20150107
    • Publication Date:
      20221213
    • Accession Number:
      10.1515/jbcpp-2014-0005
    • Accession Number:
      24620015